Spyre Therapeutics, Inc. (SYRE): Operating Income
-$209.56M
Year ended 2025-12-31
-$201.34M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$209.56M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$208.57M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$242.30M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$84.78M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$65.65M | n/m | 2024-11-18, From 2021-01-01 |
| 2020-12-31 | -$81.48M | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | -$80.33M | n/m | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | -$45.46M | n/m | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | -$27.68M | n/m | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | -$21.91M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | -$11.31M | n/m | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | -$8.90M | n/a | 2017-03-23, From 2014-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | -$209.56M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.39M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.21M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
Compare SYRE, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗